Search

The article discusses a clinical trial, NCT06634641, focusing on the assessment of clozapine-related immunodeficiency in Parkinson's disease patients. Clozapine, a second-generation antipsychotic, is commonly used to manage psychosis symptoms in Parkinson's disease. The trial aims to evaluate changes in serum immunoglobulin levels and lymphocyte subpopulations in parkinsonian patients treated with clozapine at 6 months and 1 year after treatment initiation. The study addresses concerns about clozapine-induced immunodeficiency and the need for specific exploration in Parkinson's disease patients. [Extracted from the article]

A study conducted at Vanderbilt University Medical Center in Nashville, Tennessee, focused on evaluating antibiotic de-escalation for autologous stem cell transplant patients with febrile neutropenia. The research aimed to determine the impact of early empiric antibiotic de-escalation on the duration of broad-spectrum antibiotics (BSA) and its effect on recurrent fever, documented infection, and readmission rates. The study found that implementing an early de-escalation protocol was associated with a reduction in BSA duration without significant differences in clinical outcomes, suggesting that this approach may be safe and reduce unnecessary antibiotic use for patients with febrile neutropenia. [Extracted from the article]

A recent study conducted at the University of Texas MD Anderson Cancer Center explored the use of procalcitonin (PCT) monitoring in guiding antibiotic therapy for cancer patients with febrile neutropenia. The research found that a decrease in PCT levels was associated with earlier therapy de-escalation and shorter antibiotic duration. This suggests that PCT monitoring could be beneficial in antimicrobial stewardship programs for this patient population. The study was funded by Merck & Co. and the National Institutes of Health/national Cancer Institute. [Extracted from the article]

A recent study conducted at Universitas Padjadjaran focused on infectious complications in pediatric oncology patients, particularly typhlitis and mucositis. The research highlighted the increased risk of infections in cancer patients, leading to higher morbidity and mortality rates, especially in countries with limited healthcare facilities. The study emphasized the importance of infection prevention and control, particularly in high-risk groups with low absolute neutrophil count, as these patients are more likely to experience infectious complications that can impact prognosis. [Extracted from the article]

Researchers from the University of Alabama at Birmingham conducted a study on predictors of neutropenia secondary to ganciclovir exposure during treatment of congenital cytomegalovirus disease. The study found that low baseline absolute neutrophil count (ANC) was correlated with the development of neutropenia, and high drug exposure hastened the development of neutropenia compared to low drug exposure. Further research is needed to explore if different dosing regimens affect the development of neutropenia in patients undergoing treatment for congenital cytomegalovirus disease. [Extracted from the article]

A study conducted at the King Faisal Specialist Hospital and Research Center in Saudi Arabia focused on the incidence and risk factors of neutropenia in neonates with hemolytic disease of the newborn (HDN). The research found that neutropenia, characterized by low neutrophil counts, was more prevalent in male neonates with moderate-to-severe HDN, prematurity, and low birth weight. The study concluded that neutropenia in infants with HDN is generally a benign, self-limiting condition that can be managed conservatively. [Extracted from the article]

A recent study conducted at the University of Tennessee Health Science Center focused on evaluating an intervention to decrease the length of stay in children with low-risk febrile neutropenia. The research aimed to identify a low-risk group of pediatric oncology patients who could be safely discharged early from the hospital. The study found that implementing guidelines for early discharge did not result in a reduction in hospital stay, highlighting the importance of understanding the optimal strategy for guideline implementation to improve the quality and efficiency of care for these patients. [Extracted from the article]

A study conducted at the University of Sao Paulo in Brazil examined the prevalence of Human Pegivirus-1 (HPgV-1) RNA in pediatric oncology patients with febrile neutropenia (FN). The research found that HPgV-1 RNA was detected in 23.3% of blood samples, with genotype 2 being the most common strain in Brazil. The study suggests further investigation into the role of HPgV-1 RNA in FN and its potential impact on vulnerable patient populations. [Extracted from the article]

A recent study conducted at the University of Texas MD Anderson Cancer Center focused on targeting the EGFR pathway in chemotherapy-resistant triple-negative breast cancer. The study involved a single-arm phase II trial using panitumumab, carboplatin, and paclitaxel as neoadjuvant therapy in patients with doxorubicin and cyclophosphamide-resistant TNBC. The results showed a combined pCR/RCB-I rate of 30.2%, indicating the potential efficacy of panitumumab in treating chemotherapy-resistant TNBC. The researchers suggest further evaluation of panitumumab in larger, randomized clinical trials for this patient population. [Extracted from the article]

A study conducted by researchers at China Medical University in Tainan, Taiwan, explored the association between granulocyte colony-stimulating factor (GCSF) treatment and the risk of brain metastasis in advanced stage breast cancer patients. The retrospective cohort study found that patients who received GCSF treatment had a significantly higher incidence of brain metastasis compared to those who did not receive the treatment. The researchers concluded that further large-scale observational studies are needed to confirm these preliminary results. For more information, the full article can be accessed at https://doi.org/10.3390/ijms251910756. [Extracted from the article]

Researchers at the University of Washington conducted a study on factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia (AML). The study aimed to identify characteristics that could predict which AML patients with febrile neutropenia have a lower risk of severe illness. Physiological parameters such as heart rate, blood pressure, and fever height were found to be the best predictors of low-risk admissions and infection. The study concluded that an AML-specific febrile neutropenia risk model needs further development and validation. [Extracted from the article]

Researchers at the University of Melbourne in Australia have conducted a study on preneutropenic fever (PNF) in patients with hematological malignancies. PNF refers to the development of fever after chemotherapy but before chemotherapy-induced neutropenia. The study found that a significant proportion of PNF cases did not have an infectious cause. The researchers recommend early cessation of empiric therapy after PNF in the absence of infection as an important antimicrobial stewardship intervention. This research provides valuable insights for healthcare professionals managing patients with hematological malignancies. [Extracted from the article]

A randomized, open-label, interventional, real-world study is being conducted to compare the efficacy and safety of QL0605 administered at different timepoints after chemotherapy in breast cancer patients. The study aims to determine the incidence of febrile neutropenia for the first cycle of chemotherapy as the primary outcome measure. Secondary endpoints include the incidence rates of grade 3/4 neutropenia, chemotherapy dose reduction and delay, antibiotic administration, and pain. The study is currently recruiting participants and is expected to be completed by December 30, 2025. [Extracted from the article]

A study conducted in Tokyo, Japan, aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis using pegfilgrastim in breast cancer patients receiving chemotherapy. The study analyzed data from 296 Japanese patients with breast cancer who were divided into pegfilgrastim and non-pegfilgrastim groups. The results showed that the pegfilgrastim group had a significantly higher median total cost, primarily due to the prophylactic use of pegfilgrastim. However, there was no significant difference in the 3-year overall survival between the two groups. The study suggests that pegfilgrastim should be used during chemotherapy based on patient-related FN risk factors rather than routine use. [Extracted from the article]

A study conducted by researchers at the Avera Cancer Institute in Sioux Falls, South Dakota, examined the timing of pegfilgrastim administration in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide (ddAC) chemotherapy. The study found that administering pegfilgrastim on the same day as chemotherapy led to a significant increase in neutropenic complications, including febrile neutropenia, acute care visits, grade >= 3 neutropenia, chemotherapy dose reductions, and antibiotic use. The researchers concluded that pegfilgrastim should be administered the day after chemotherapy in breast cancer patients receiving ddAC. This study provides important insights for healthcare providers and patients regarding the optimal timing of pegfilgrastim administration to prevent chemotherapy-induced febrile neutropenia. [Extracted from the article]

A recent study conducted by the Department of Pediatric Oncology explores the outpatient management of fever and neutropenia in low-risk children with solid tumors. The researchers aimed to increase outpatient management for eligible patients and implemented a standardized algorithm to achieve this goal. The study found that 71% of eligible patients were successfully managed as outpatients, with only 6% developing bacteremia and requiring hospital admission. The research emphasizes the importance of engaging parents and caregivers in this practice change for successful implementation. [Extracted from the article]

A new report from Bern University Hospital in Switzerland presents fresh data on neutropenia, a condition characterized by a low count of neutrophils in the blood. The study focused on isolated severe neutropenia in adults and aimed to identify underlying causes and analyze management and outcomes. The researchers found that isolated severe neutropenia is rare, even in a tertiary hospital, and identified drugs and infections as the main underlying causes. The study highlights the need for diagnostic work-up and management strategies for this condition, including raising awareness about the use of certain medications and considering therapy for chronic forms of neutropenia. [Extracted from the article]

A recent study conducted at the Institute for Oncology and Radiology of Serbia has found that serum albumin levels can serve as a prognostic biomarker for febrile neutropenia (FN) outcomes and complications in cancer patients. The study enrolled 185 adult cancer patients experiencing FN episodes and assessed their serum albumin levels. The results showed that serum albumin levels displayed promising prognostic utility in FN, with moderate specificity and sensitivity in predicting mortality and complications. Integrating serum albumin into existing risk assessment frameworks improved predictive capabilities and aided clinicians in identifying high-risk patients. However, further research is needed to optimize the sensitivity and specificity of serum albumin as a biomarker. [Extracted from the article]

A recent study conducted at the University of Verona in Italy examined the effectiveness of different treatment regimens for mantle cell lymphoma (MCL). The researchers found that bendamustine-rituximab (BR) followed by rituximab maintenance (R) was an effective induction regimen, particularly for older patients. The study also found that the addition of bortezomib or lenalidomide to the treatment did not improve progression-free survival and was associated with increased risks of neutropenia and other adverse events. This research provides valuable insights into the optimal treatment options for MCL patients. [Extracted from the article]

A recent study conducted by researchers at the Affiliated Tumor Hospital of Harbin Medical University evaluated the efficacy and safety of a novel long-acting granulocyte colony-stimulating factor (G-CSF) called F-627 (efbemalenograstim alfa) in reducing neutropenia in breast cancer patients undergoing chemotherapy. The study found that a single fixed dose of F-627 was as safe and effective as a daily dose of filgrastim in reducing neutropenia and its complications. The results were consistent across multiple cycles of chemotherapy. This research provides valuable insights into potential treatment options for breast cancer patients. [Extracted from the article]

A recent study conducted at the University of Electronic Science and Technology of China examined the predictive value of hematological parameters for febrile neutropenia (FN) in patients with cancer. The study analyzed blood cell counts and clinical information from 4,130 patients with solid tumors who were undergoing chemotherapy. The researchers found that certain hematological markers, such as lower post-chemotherapy lymphocyte count and higher change percentage of post-chemotherapy neutrophil count, were associated with an increased risk of FN. These findings suggest that peri-chemotherapy hematological markers can improve the prediction of FN in cancer patients. [Extracted from the article]

A recent study conducted at the Beth Israel Deaconess Medical Center focused on the evaluation of empiric antibacterial treatment (EAT) and subsequent de-escalation for febrile neutropenia (FN). FN is a common complication of chemotherapy-induced neutropenia that affects a significant number of patients with hematologic malignancies. The study aimed to reevaluate the duration of EAT in patients with FN without a documented source of infection. The research found that rates of EAT de-escalation improved by 12% compared to a previous study in 2019, and the mean duration of overall EAT was three days less in 2023. However, there was an increase in adverse effects, particularly C. difficile infection (CDI), in 2023. The study suggests that further improvements in practice can be achieved through dedicated time for antimicrobial stewardship review, clinician education, and guideline-driven alerts for review. [Extracted from the article]

A recent report discusses research conducted at Hacettepe University Faculty of Medicine in Ankara, Turkey, on the management of febrile neutropenia (FN) and the use of a computerized decision support system (CDSS). The study included 227 FN patients between April 2016 and January 2019. The researchers found that the introduction of a local guideline improved the appropriateness of initial empirical treatment and reduced the need for escalation of antibacterial treatment in FN patients. The CDSS also showed high compliance with the local guideline-based decisions, highlighting its usefulness for these patients. [Extracted from the article]

A recent study conducted at the National University of Medical Sciences (NUMS) in Pakistan examined the frequency and management outcomes of neutropenia in women with breast cancer who were receiving anthracycline-based chemotherapy. The study included 200 patients with breast cancer who underwent three or four cycles of chemotherapy. Neutropenia, a condition characterized by low levels of neutrophils in the blood, was observed in 32.1% of the cycles, with 24.4% of cases classified as grade III or IV neutropenia. Treatment with granulocyte colony-stimulating factor (G-CSF) was found to be effective in improving neutropenia in 83.3% of patients. The study highlights the presence of neutropenia in post-menopausal patients with advanced breast cancer and the efficacy of G-CSF as a treatment option. [Extracted from the article]

Researchers from AFMC in Maharashtra, India have published a case report on Felty's syndrome, a rare and serious complication of Rheumatoid Arthritis (RA). Felty's syndrome is characterized by a triad of RA, splenomegaly (enlarged spleen), and neutropenia (low neutrophil count). The report presents the case of a 44-year-old female with a three-year history of RA who developed ascites and was found to have portal hypertension. The diagnosis of Felty's syndrome was confirmed based on the triad of symptoms, highlighting the importance of early recognition and management to prevent severe complications. [Extracted from the article]

A recent study conducted by researchers at Emory University School of Medicine explored the use of abemaciclib, a CDK 4/6 inhibitor, in combination with radiation therapy for the treatment of diffuse intrinsic pontine glioma (DIPG) in children. The study aimed to determine the maximum tolerated dose of abemaciclib and assess its toxicity and pharmacokinetic profile. The results showed that abemaciclib was well-tolerated, with mainly low-grade hematologic toxicity and diarrhea. The median progression-free survival for all patients was 7.5 months, and the median overall survival was 12.4 months. [Extracted from the article]

A study conducted at the University Medical Center Hamburg-Eppendorf in Germany focused on neutropenia, a condition characterized by a low count of neutrophils, a type of white blood cell. The study examined two patients with JAGN1 mutations who were unresponsive to granulocyte colony-stimulating factor (G-CSF) therapy. The researchers administered granulocyte-macrophage colony-stimulating factor (GM-CSF) as an alternative treatment, but it did not increase neutrophil counts or improve the patients' clinical symptoms. The study suggests that patients with JAGN1-mutant severe congenital neutropenia and reduced G-CSF responsiveness should be considered for early stem cell transplantation. [Extracted from the article]

A recent report from the Department of Breast Surgery discusses the case of a 56-year-old female patient who was scheduled for breast cancer surgery but was unexpectedly diagnosed with autoimmune neutropenia (AIN), a rare condition with no effective treatment. The surgery was postponed, and the patient underwent endocrine therapy for 7 months before the surgery was performed. Despite the administration of granulocyte colony-stimulating factor, the patient's neutrophil count did not increase, and levofloxacin was given during the surgery. The patient experienced fever after the surgery but recovered and was discharged on the sixth day. This case highlights the challenges and complications associated with AIN in breast cancer surgery patients. [Extracted from the article]

A recent study conducted at MacKay Memorial Hospital in Taipei, Taiwan, examined the use of prophylactic granulocyte-colony stimulating factor (G-CSF) in children with acute lymphoblastic leukemia (ALL) who underwent induction chemotherapy. The study found that the use of G-CSF prophylaxis significantly reduced episodes of febrile neutropenia in high-risk ALL patients. However, the reduction in severe infections did not reach statistical significance during G-CSF administration. The study also identified several clinical factors, such as severe ileus, oral mucositis, hyperglycemia, central venous catheter placement, and prolonged neutropenia, that were associated with a higher risk of bloodstream infections in ALL patients receiving induction chemotherapy. [Extracted from the article]

The article investigates risk factors for adverse outcomes in children with febrile neutropenia associated with hematological malignancies. Topics include the clinical and hematological profiles of patients, common chemotherapy drugs leading to febrile neutropenia, and factors linked to poor outcomes such as profound neutropenia, low hemoglobin, low platelet count, and microbiologically confirmed infections.

The article highlights research from Hospital Infantil de Mexico Federico Gomez on the cost-effectiveness of outpatient management for febrile neutropenia in pediatric cancer patients. Topics include a cost-minimization analysis revealing significant savings with outpatient care, reduced hospital stay durations, and decision-making implications for the Mexican public healthcare system.

A study conducted by investigators at the All India Institute of Medical Sciences (AIIMS) in Odisha, India, aimed to determine the usefulness of procalcitonin (PCT) and C Reactive protein (CRP) as biomarkers for patients with acute lymphoblastic leukemia/lymphoma (ALL) and febrile neutropenia (FN). The study included patients aged 15 years and older. The results showed that serial monitoring of PCT can be used as a supplement to clinical decision making, and PCT levels at 48 hours of starting antibiotic therapy can be used for early augmentation of antibiotic therapy to prevent complications of FN in patients undergoing treatment for ALL. [Extracted from the article]

A recent study conducted by researchers from Capital Medical University investigated the efficacy and safety of mecapegfilgrastim, a biosimilar of pegfilgrastim, in preventing febrile neutropenia (FN) in pediatric and adolescent patients with rhabdomyosarcoma (RMS) or Ewing sarcoma (ES). The study found that mecapegfilgrastim showed acceptable efficacy and safety profiles in these patients. Two out of 30 patients experienced FN after the first cycle of chemotherapy, and eight patients experienced grade 4 neutropenia after receiving prophylactic mecapegfilgrastim. The researchers concluded that further randomized studies with larger sample sizes are needed. [Extracted from the article]

A recent study conducted at the University of Texas MD Anderson Cancer Center explored the adverse effects of immune checkpoint inhibitors (ICIs) on patients with unresectable hepatocellular carcinoma (HCC). The researchers reported a case of severe febrile neutropenia and pancytopenia in a patient who received atezolizumab and bevacizumab therapy. The patient experienced symptoms such as fever, headache, vomiting, chills, pain, fatigue, and a rash. The study highlights the importance of considering hematological immune-related adverse events (hem-irAEs) in patients undergoing ICIs treatment. [Extracted from the article]

A recent study conducted by the University of Chile examined the incidence of invasive fungal diseases (IFD) in children with cancer in Chile between 2016 and 2020. The study found a significant increase in IFD compared to the period between 2004 and 2006. The incidence rate of IFD was calculated to be 14.6% during the study period, with an incidence rate of 13.6 IFD cases per 1000 days of neutropenia. These findings highlight the changing epidemiology of IFD in immunocompromised children and emphasize the need for further research and preventive measures. [Extracted from the article]

Researchers from Harvard Medical School have conducted a study on gene therapy for severe congenital neutropenia, a bone marrow disorder characterized by low neutrophil counts. The study focused on patients with early exon nonsense mutations in the ELANE gene, which is often associated with the condition. The researchers found that introducing frameshift/nonsense mutations in the mutant ELANE gene could restore neutrophil counts, providing a potential model for gene therapy. The study supports the use of gene therapy approaches for severe congenital neutropenia. [Extracted from the article]

The article offers information on the effectiveness of elemental diets in preventing adverse events during chemotherapy for esophageal cancer patients. Topics discussed include the impact of elemental diets on gastrointestinal and hematological toxicities; the statistical significance of these effects; and the potential benefits for preventing neutropenia and leucopenia.

The article offers information on a study comparing imipenem/cilastatin/relebactam (IPM/REL) with standard-of-care antibiotics for treating febrile neutropenia in cancer patients. Topics discussed include the efficacy and safety of IPM/REL versus standard antibiotics; the impact of antibiotic resistance; and the potential need for updating current treatment protocols.

The article offers information on the effectiveness of Methicillin-resistant Staphylococcus aureus (MRSA) nares screening for predicting infections among transplant recipients and patients with neutropenia. Topics discussed include the screening's high negative predictive value (NPV) across various anatomical sites; its utility in reducing anti-MRSA therapy; and its reliability for different patient groups including those with neutropenia and transplant recipients.

The article offers information on the clinical profile and management of febrile neutropenia in children with malignancies. Topics discussed include the prevalence of infectious agents and their antibiotic susceptibility; the impact of central line-associated infections; the outcomes associated with different pathogens; and also emphasizing the need for vigilant and protocol-based management.

A recent report from the University of Chile discusses the epidemiology and potential role of respiratory viral infections in children with cancer and febrile neutropenia, as well as in children undergoing hematopoietic stem cell transplantation. The use of molecular diagnostic techniques has allowed for early detection of respiratory viral infections, leading to more rational use of antimicrobials in this vulnerable population. Recent randomized clinical studies have shown that in selected patients with negative bacterial cultures, it is safe and effective to discontinue antimicrobials. However, more evidence is needed for a similar indication in children undergoing hematopoietic stem cell transplantation with viral respiratory infection episodes. Understanding the role of respiratory viral infections in immunocompromised children may contribute to a more rational use of antimicrobials and help decrease antimicrobial resistance in this population. [Extracted from the article]

A recent study conducted by researchers at Hainan Medical University in China focused on the oral health management of children with severe congenital neutropenia (SCN) and periodontitis. SCN is a rare genetic disease characterized by low levels of neutrophils, a type of white blood cell. The study described the diagnosis and treatment of a child with SCN and periodontitis, highlighting the importance of individualized treatment plans to effectively control the interaction between SCN and periodontal disease and reduce the occurrence of serious infections. The findings suggest that periodontal treatment, along with hematopoietic stem cell transplantation, can improve oral hygiene and reduce symptoms of periodontitis in children with SCN. [Extracted from the article]

A recent report from the Icahn School of Medicine at Mount Sinai discusses research findings on neutropenia, specifically atypical chemokine receptor-1 (ACKR1)/Duffy antigen receptor of chemokines (DARC)-associated neutropenia (ADAN). ADAN, previously known as benign ethnic neutropenia, is found in two-thirds of individuals identifying as Black in the USA and is associated with mild to moderate decreases in peripheral neutrophil counts. However, it does not lead to increased infections. Recent studies suggest that neutrophils may redistribute from peripheral blood to tissues, such as the spleen, which may explain why ADAN does not increase infection risks. The research provides insights into the biology of neutrophils and their trafficking, which may inform the clinical interpretation of neutropenia in ADAN. While ADAN does not diminish host defense like other forms of neutropenia, it may lead to increased proinflammatory signaling, potentially affecting the immune system's senescence, predisposition to autoimmunity, and cancer. [Extracted from the article]